Spyre Therapeutics Statistics
Total Valuation
SYRE has a market cap or net worth of $7.85 billion. The enterprise value is $6.70 billion.
| Market Cap | 7.85B |
| Enterprise Value | 6.70B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SYRE has 88.17 million shares outstanding. The number of shares has increased by 31.80% in one year.
| Current Share Class | 88.17M |
| Shares Outstanding | 88.17M |
| Shares Change (YoY) | +31.80% |
| Shares Change (QoQ) | +7.87% |
| Owned by Insiders (%) | 5.72% |
| Owned by Institutions (%) | 110.17% |
| Float | 82.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.21 |
| P/TBV Ratio | 8.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.53
| Current Ratio | 18.53 |
| Quick Ratio | 18.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -22.98% and return on invested capital (ROIC) is -21.79%.
| Return on Equity (ROE) | -22.98% |
| Return on Assets (ROA) | -19.81% |
| Return on Invested Capital (ROIC) | -21.79% |
| Return on Capital Employed (ROCE) | -24.45% |
| Weighted Average Cost of Capital (WACC) | 21.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 125 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +444.19% in the last 52 weeks. The beta is 3.11, so SYRE's price volatility has been higher than the market average.
| Beta (5Y) | 3.11 |
| 52-Week Price Change | +444.19% |
| 50-Day Moving Average | 96.30 |
| 200-Day Moving Average | 67.04 |
| Relative Strength Index (RSI) | 45.73 |
| Average Volume (20 Days) | 1,267,615 |
Short Selling Information
The latest short interest is 12.13 million, so 13.76% of the outstanding shares have been sold short.
| Short Interest | 12.13M |
| Short Previous Month | 11.86M |
| Short % of Shares Out | 13.76% |
| Short % of Float | 14.77% |
| Short Ratio (days to cover) | 10.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | -215.80M |
| Operating Income | -271.34M |
| Pretax Income | -178.92M |
| Net Income | -150.21M |
| EBITDA | n/a |
| EBIT | -271.34M |
| Earnings Per Share (EPS) | -$2.01 |
Balance Sheet
The company has $1.15 billion in cash and no debt, with a net cash position of $1.15 billion or $12.99 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | n/a |
| Net Cash | 1.15B |
| Net Cash Per Share | $12.99 |
| Equity (Book Value) | 1.10B |
| Book Value Per Share | 10.84 |
| Working Capital | 1.11B |
Cash Flow
| Operating Cash Flow | -208.94M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -208.94M |
| FCF Per Share | -$2.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.80% |
| Shareholder Yield | -31.80% |
| Earnings Yield | -1.91% |
| FCF Yield | -2.66% |
Analyst Forecast
The average price target for SYRE is $120.08, which is 34.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $120.08 |
| Price Target Difference | 34.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |